{"id":"NCT00128492","sponsor":"Gilead Sciences","briefTitle":"Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA)","officialTitle":"A Phase 3, Open-label, Follow-On Study of Multiple Courses of Aztreonam Lysinate for Inhalation (AI) in Cystic Fibrosis Patients (AIR-CF3)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-08","primaryCompletion":"2008-11","completion":"2009-01","firstPosted":"2005-08-10","resultsPosted":"2011-03-11","lastUpdate":"2011-05-19"},"enrollment":274,"design":{"allocation":"NON_RANDOMIZED","model":null,"masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"AZLI 75 mg two times a day (BID)/ three times a day (TID)","otherNames":[]}],"arms":[],"summary":"The purpose of this study was to evaluate the safety and efficacy of multiple courses of AZLI in patients with cystic fibrosis (CF) and lung infection due to Pseudomonas aeruginosa (PA).","primaryOutcome":{"measure":"Number of Participants Reporting Adverse Events (AEs)","timeFrame":"Overall study (72 weeks) included nine 28-day courses of study drug alternating with nine 28-day courses off drug","effectByArm":[{"arm":"75 mg AZLI Two Times a Day (BID)","deltaMin":83,"sd":null},{"arm":"75 mg AZLI Three Times a Day (TID)","deltaMin":185,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":11},"locations":{"siteCount":65,"countries":["United States","Australia","Canada","New Zealand"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":38,"n":85},"commonTop":["Cough","Productive cough","Exercise tolerance decreased","Respiratory tract congestion","Pharyngolaryngeal pain"]}}